HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Why Did Germany’s Switch Committee Reject Perrigo’s OTC Daily Contraceptive Proposal?

Executive Summary

Skepticism about the need for widening access to the progestogen-only contraceptive pill, fears of associated thrombosis risk with use and the potential cost barriers were among the many reasons for the unanimous rejection of Perrigo's Rx-to-OTC switch application for desogestrel (75μg) for oral use.

You may also be interested in...

Perrigo Ships Opill To Stores, But Contraceptive Access Advocates Say It Doesn’t Deliver On Price

First US OTC daily oral contraceptive shipped to major retailers and pharmacies and will be available on shelves nationwide and online later in March. Perrigo says pre-orders for Opill are available currently from select online retailers.

Maxwellia Adds STI Home-Test To UK Lovi Line

UK sexual health specialist Maxwellia continues to expand its UK footprint with an STI home-test launch under the Lovi brand umbrella. 

Infant Formula Production Expansion Brings Problems Souring Perrigo's 2024 Forecast

Perrigo doesn’t attempt to diminish significance of challenge to regain sales growth in formula market as it resets its plants. Analysts see formula business as only current impediment to stronger results.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts